Ahmed Negida, MD, PhD
@ahmednegida.bsky.social
Postdoctoral Scholar @VCUHealth | Formerly @HarvardMed | Global Lead @Global_Nsurg | #Neurology #Neurosurgery | Instructor @NegidaAcademy
A little is known about how these groups differ in biomarker profiles and disease progression trajectories. Most importantly, how can patients be stratified prospectively into these groups? This is important for external validation and translation into disease-modification trials.
May 4, 2025 at 4:04 PM
A little is known about how these groups differ in biomarker profiles and disease progression trajectories. Most importantly, how can patients be stratified prospectively into these groups? This is important for external validation and translation into disease-modification trials.